EVO Profile
Evotec SE is a leading global drug discovery and development partner, specializing in providing comprehensive solutions for the pharmaceutical and biotechnology industries. The company supports its clients through the entire drug development process, from early-stage discovery to clinical development. Evotec's expertise spans a wide range of therapeutic areas, including diabetes and its complications, fibrosis, infectious diseases, central nervous system (CNS) disorders, oncology, pain and inflammation, immunology, rare diseases, respiratory conditions, and women's health.
The company collaborates with a diverse array of industry leaders and innovators, reflecting its strong position in the drug development sector. Notable partners include Bayer AG, Eli Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd., Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. These partnerships enable Evotec to leverage cutting-edge technologies and advanced methodologies to accelerate the development of novel therapeutics.
Evotec's integrated platform combines high-throughput screening, advanced in vitro and in vivo models, and sophisticated data analytics to drive drug discovery and development. The company's capabilities extend to drug formulation, optimization, and preclinical testing, providing a comprehensive suite of services designed to meet the needs of its clients. Evotec's approach emphasizes innovation and efficiency, aiming to shorten development timelines and reduce costs while enhancing the success rate of new drug candidates.
Founded in 1993 and headquartered in Hamburg, Germany, Evotec SE was previously known as Evotec AG before rebranding in April 2019. The company has established a global presence, with research and development facilities and operations strategically located to support its extensive network of partnerships and collaborations. Evotec's commitment to advancing drug discovery and development continues to drive its growth and leadership in the biopharmaceutical industry
|
